Appointment of Chief Medical Officer

Tiziana at J.P. Morgan Healthcare Conference 2021

Tiziana to Present at Biotech Showcase Digital

Second Price Monitoring Extn

Price Monitoring Extension

Completion of Foralumab Clinical Trial in Brazil

Publication of Prospectus

Notification of Admission to the Main Market

Director/PDMR Shareholding

Tiziana Life Sciences to Host Investor Update Call

Director/PDMR Shareholding

Phase 1b/2 Clinical Trial - Crohn's Disease

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Initiation of Clinical Trial for COVID-19 Patients

Exercise of Options, Issue of Equity, PDMR Dealing

Demerger Update and Timetable Confirmation

Issue of Equity on Exercise of Warrants

Demerger of StemPrintER

Exercise of Options, Issue of Equity, PDMR Dealing

Issue of Equity on Exercise of Warrants

Exercise of Options, Issue of Equity, PDMR Dealing

Issue of Equity on Exercise of Warrants

Result of GM

Half-year Report

Second Price Monitoring Extn

Price Monitoring Extension

Interview - Bloomberg International

Publication of Research Note

Issue of Equity and Total Voting Rights

Clinical Study with Nasally Administered Foralumab

Second Price Monitoring Extn

Price Monitoring Extension

Demerger of StemPrintER and Distribution in Specie

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Holding(s) in Company

ADS Registration Statement Filing Clarification

Exercise of Warrants and Issue of Equity

Tiziana CEO Interview

Grant of Options - Director Dealings

Patent Granted for Anti-IL-6/IL-6

Patent Granted for Milciclib

Update - Scientific Advisory Board

Second Price Monitoring Extn

Price Monitoring Extension

Patent Granted for Foralumab

BTIG's Virtual Biotechnology Conference

Holding(s) in Company

Closing of $57.25 Million Offering

Expedited Clinical Development Plan

Issue of Equity

Total Voting Rights

Second Price Monitoring Extn

Price Monitoring Extension

Submission of a Patent Application for Foralumab

Proposed Admission to the Official List

Update on Timings and Corporate Actions

Investor Webinar to Provide Corporate Updates

Second Price Monitoring Extn

Price Monitoring Extension

Exercise of Warrants and Issue of Equity

Director Appointment

Second Price Monitoring Extn

Price Monitoring Extension

Result of AGM

Submission of Patent Application

Change to ADS Ratio - Updated

Change to ADS Ratio

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Total Voting Rights and StemPrintER Update

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19

Agreement with STC Biologics

Notice of AGM

Exercise of Warrants and Issue of Equity

Second Price Monitoring Extn

Price Monitoring Extension

Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases

Patent Granted for Oral Administration

Directorate Change

Final Results

Extension of At the Market Sales Agreement

Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease

Anti-CD3 for Alzheimer Disease

Correction Issue of Equity and Total Voting Rights

Issue of Equity and Total Voting Rights

Change of Adviser

Further re: ASCO Conference - StemPrintER

Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company

Intention to Demerge StemPrintER

Holding(s) in Company

Exercise of Warrants and Issue of Equity

Second Price Monitoring Extn

Price Monitoring Extension

Tiziana Lifesciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma

ASCO Conference - Milciclib

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

ASCO Conference - StemPrintER

Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society o

Second Price Monitoring Extn

Price Monitoring Extension

Holding(s) in Company

ASCO Conference

Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference

Second Price Monitoring Extn

Price Monitoring Extension

Result of GM

Holding(s) in Company

Total Voting Rights

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses

Price Monitoring Extension

Patent Application Filing

Issue of Equity and Update on AIM Cancellation

Second Price Monitoring Extn

Price Monitoring Extension

Notice of GM

Second Price Monitoring Extn

Price Monitoring Extension

Further Re: Block Listing Application

Second Price Monitoring Extn

Price Monitoring Extension

Block Listing Application

Issue of Equity

Second Price Monitoring Extn

Price Monitoring Extension

Second Price Monitoring Extn

Price Monitoring Extension

Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies

Tiziana Develops Treatment For COVID-19 Patients

Closing of Offer

Tiziana U.S. Follow-On Offering of $10 million

TZLS-501 / COVID-19

Result of GM

Proposed U.S. Public Offering of ADSs

Director/PDMR Shareholding

Notice of GM

Filing of SEC Form F-3

Director Appointment

Director/PDMR Shareholding

Proposed Cancellation from AIM

Further re: Foralumab Phase 1 Trial

Director/PDMR Shareholding

Foralumab Phase 1 Trial

Issue of Equity and Directorate Change

Issue of CLN

Change to ADS ratio

Half-year Report

Further re: Update on IND Application

Phase 1 Clinical Data

Phase 2a Clinical Data

Second Price Monitoring Extn

Price Monitoring Extension

Proposed U.S. Public Offering

Phase 2a Clinical Data

Teplizumab Article

Second Price Monitoring Extn

Price Monitoring Extension

Change of Adviser

Director/PDMR Shareholding

Article on Clinical Activity of OKT3

Director/PDMR Shareholding

Director/PDMR Shareholding

PDMR Dealings

Result of AGM

9th Annual LD Micro Invitational

Notice of AGM

Director/PDMR Shareholding

Update on IND Application

Director/PDMR Shareholding

Second Price Monitoring Extn

Price Monitoring Extension

Reissue: Interim Clinical Data

Interim Clinical Data

Holding(s) in Company

Holding(s) in Company

Holding(s) in Company

Final Results

IND Application Submitted for NASH Oral Treatment

Directorate Change

Exercise of Warrants & Issue of Equity

Milciclib HCC Phase IIa Trial Enrollment Completed

Foralumab: Phase 1 Trial with Nasal Administration

Holding(s) in Company

Statement re: ADSs

Closing of Offering and Total Voting Rights

Discounted exercise prices of outstanding warrants

Offer Pricing, Nasdaq Listing & Loan Conversion

Issue of Equity

Amended Registration Statement filed with the SEC

Milciclib synergistic activity presented at AASLD

Tiziana announces Offering & Application to Nasdaq

U.S. FDA Approval IND Nasal Foralumab Phase 1

Interim Results for Six Months Ended 30 June 2018

PDMR Dealing

PDMR dealings

PDMR Dealing

PDMR Dealing

PDMR dealings

PDMR Dealing

PDMR Dealing

Filing of Investigational New Drug application

US Registration Statement for Proposed Offering

Result of AGM

Appointment of Broker

Final Results

Notice of AGM

Second Price Monitoring Extn

Price Monitoring Extension

Placing

Placing

Statement re broker

Placing to raise £600,000 and issue of equity

Appointment of Director

Appointment of Broker

Presentation at ASCO 3 June 2018

License Agreement

Subscription

Issue of Equity

Grant of Options - Director Dealing

Milciclib Phase 2a Trial - Tolerability Update